Trial intelligence / Profile preview

Pemetrexed and Apatinib Maintenance in Advanced Non-squamous NSCLC

NCT03792503Phase 4

Key facts

Status: Withdrawn
Start: Feb 2019
Primary completion: Feb 2020
Countries: 1
Sponsor: Xinqiao Hospital

Drugs: Rivoceranib
Conditions: Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)

Overview

Phase 4, open-label, single-arm trial of Rivoceranib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Xinqiao Hospital. Primary endpoint: Progression-Free Survival at 3 years. Planned start Feb 2019; status: withdrawn.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Apatinib + Pemetrexed
Maintenance therapy for patients who did not progress after 4 cycles of induction chemotherapy.

Who it enrols

Patients with Stage IV non-squamous NSCLC who have not progressed after 4 cycles of pemetrexed and platinum-based induction chemotherapy, excluding those with EGFR or ALK mutations.

Endpoints

Primary

Progression-Free Survival3 years

Secondary

Overall Survival3 years
Disease Control Rate3 years
Objective Response Rate3 years
Health Related Quality of Life3 years

Beyond the preview

Go deeper on NCT03792503.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03792503.